Brought to you by 
Oncoheroes gains worldwide license to BI's shelved volasertib cancer compound
20 Sep 2019
Executive Summary
Boehringer Ingelheim International GmbH licensed Oncoheroes Biosciences Inc. exclusive worldwide R&D and commercialization rights (and related IP) to its volasertib (BI6727), a polo-like-kinase 1 (PLK1) inhibitor for cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncoheroes gains worldwide license to BI's shelved volasertib cancer compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice